Caffeic acid phenethyl ester ameliorates cerebral infarction in rats subjected to focal cerebral ischemia.
The effects of caffeic acid phenethyl ester (CAPE), an antioxidant derived from propolis, on the infarct volume elicited by focal cerebral ischemia were studied on Long-Evans rats. Cerebral infarction was induced by microsurgical procedures with ligation of the right middle cerebral artery (MCA) and clipping of bilateral common carotid arteries (CCA) for 60 min. The rats were sacrificed 24 h later and serial brain slices of 2 mm thickness were taken and stained for the measurement of infarct area. CAPE was administered intravenously 15 min before MCA occlusion. Pretreatment of CAPE (0.1, 1 and 10 microg/kg) significantly reduced the total infarct volume from 169.6 +/- 14.5 mm3 (control) to 61.0 +/- 24.1 mm3 (0.1 microg/kg CAPE), 47.4 +/- 9.1 mm3 (1 microg/kg CAPE), and 42.4 +/- 8.7 mm3 (10 microg/kg CAPE), respectively. Plasma nitric oxide (NO) content was significantly increased in rats subjected to focal cerebral ischemia. It is concluded that CAPE possesses neuroprotective properties in focal cerebral ischemia injury in rats possibly through its antioxidant effect and/or via the upregulation of NO production.
Tsai
Shen-Kou
SK
Department of Anesthesiology, College of Medicine, Buddhist Tzu-Chi University and Hospital, National Taiwan University, Taipei Veterans General Hospital, Taipei, Taiwan.
Lin
Min-Jon
MJ
Liao
Pei-Hu
PH
Yang
Chi-Yea
CY
Lin
Su-Man
SM
Liu
Sheng-Ming
SM
Lin
Ruey-Hseng
RH
Chih
Chun-Lien
CL
Huang
Shiang-Suo
SS
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001783:Blood Flow Velocity / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002109:Caffeic Acids / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000097:blood; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D020318:Rats, Long-Evans; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000503:physiopathology
D000975:Antioxidants; D002109:Caffeic Acids; D018696:Neuroprotective Agents; D009569:Nitric Oxide; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol